Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin versus cisplatin in extracranial malignant germ cell tumours
NL-OMON59988Phase 3Active, not recruiting
- Sponsor
- University of Bonn
- Start
- Jun 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin and cisplatin in Extracranial malignant germ cell tumor (EMGCT) (2 arms), sponsored by University of Bonn. Primary endpoint: Event-free survival from randomization. Started Jun 2023; status: active, not recruiting.
02
Drugs
carboplatincisplatin
03
Conditions
Extracranial malignant germ cell tumor (EMGCT)
Beyond the preview
Go deeper on NL-OMON59988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59988.